In this economic evaluation, annual MRI and potential MRI-guided biopsy for prostate cancer found improved economic value compared with standard biopsy for men with a serum PSA level of 2.5 ng/mL or more beginning at 65 years of age. The gene discussed is KLK3; the disease is Familial prostate cancer.